Usefulness of CD56, BRAF and CD15 in the differential diagnosis of thyroid lesions with nuclear features of papillary carcinoma

INTRODUCTION: Differential diagnosis of thyroid lesions with papillary carcinoma-like nuclear features includes low-risk entities, such as follicular thyroid neoplasia with papillary-like nuclear features (NIFTP), and high-risk entities, such as the tall cell subtype of papillary thyroid carcinoma (...

Descripción completa

Detalles Bibliográficos
Autores: Onieva Carbajo, Ricard, Ferreres Piñas, Joan Carles|||0000-0001-7742-0239, Alcalà Lorente, Marta, Capel Flores, Ismael|||0000-0003-2155-6764, Cano, Albert|||0000-0002-2804-3745, Bella Burgos, Berta|||0000-0003-2897-0335, Guirao Garriga, Francisco Javier, Pérez-Riverola, Víctor, Escoda Giralt, Maria Rosa, Barcons Vilaplana, Santiago, Monmany Badia, Roser, El Hamshari Rebollo, Khalid, Padilla Navas, Catalina, Bella-Cueto, Maria Rosa|||0000-0002-5144-0490
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:321160
Acceso en línea:https://ddd.uab.cat/record/321160
https://dx.doi.org/urn:doi:10.1016/j.prp.2025.156030
Access Level:acceso embargado
Palabra clave:Thyroid
Papillary carcinoma
Tall cell subtype
NIFTP
Descripción
Sumario:INTRODUCTION: Differential diagnosis of thyroid lesions with papillary carcinoma-like nuclear features includes low-risk entities, such as follicular thyroid neoplasia with papillary-like nuclear features (NIFTP), and high-risk entities, such as the tall cell subtype of papillary thyroid carcinoma (TCS). Morphological criteria are essential to distinguish them, but having immunohistochemical techniques to discriminate between these entities would be desirable. MATERIALS AND METHODS: 8 TCS, 27 papillary carcinomas of classic subtype (CS) and 20 NIFTP were selected. Immunohistochemical staining for BRAF, CD56, B-Catenin, CD15, Muc-1 and Napsin A was performed for each case and correlated with the histological diagnosis. RESULTS: All TCS cases were positive for BRAF and CD15 (p < 0.05 compared to CS) and none showed positivity for CD56. In the comparison of papillary carcinoma (TCS and CS) and NIFTP, immunostaining for BRAF, CD56 and CD15 showed statistically significant differences. CONCLUSIONS: BRAF, CD56 and CD15 immunostaining are useful to differentiate between NIFTP, CS and TCS, making it possible to identify a group of tumours with the combination CD56 negative, BRAF positive and CD15 positive that includes 100 % of TCS and 35 % of CS and a group of CD56 positive, BRAF negative and CD15 negative tumours that includes 52 % of NIFTP and 7 % of CS, facilitating the diagnosis.

Similares en LA Referencia